Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Immutep (IMMP) stocks in Canada

Learn how to easily invest in Immutep stocks.

Immutep is a biotechnology business based in the US. Immutep stocks (IMMP.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.73 – a decrease of 5.14% over the previous week. Immutep employs 0 staff and has a trailing 12-month revenue of around $3.9 million.

How to buy shares in Immutep

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IMMP – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Immutep stock price (NASDAQ:IMMP)

Use our graph to track the performance of IMMP stocks over time.

Immutep shares at a glance

Information last updated 2022-01-17.
Latest market close$3.14
52-week range$2.20 - $5.44
50-day moving average $3.56
200-day moving average $3.82
Wall St. target price$8.64
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.36

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Immutep stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Immutep price performance over time

Historical closes compared with the close of $3.14 from 2022-01-18

1 week (2022-01-08) N/A
1 month (2021-12-17) -7.92%
3 months (2021-10-18) -24.34%
6 months (2021-07-19) -12.78%
1 year (2021-01-19) -6.27%
2 years (2020-01-17) 46.05%
3 years (2019-01-18) 44.04%
5 years (2017-01-19) 26.61%

Immutep financials

Revenue TTM $3.9 million
Gross profit TTM $-13,373,974
Return on assets TTM -19.1%
Return on equity TTM -56.12%
Profit margin 0%
Book value $0.98
Market capitalisation $247.9 million

TTM: trailing 12 months

Immutep share dividends

We're not expecting Immutep to pay a dividend over the next 12 months.

Have Immutep's shares ever split?

Immutep's shares were split on a 3:10 basis on 27 December 2016. So if you had owned 10 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Immutep shares – just the quantity. However, indirectly, the new 233.3% higher share price could have impacted the market appetite for Immutep shares which in turn could have impacted Immutep's share price.

Immutep share price volatility

Over the last 12 months, Immutep's shares have ranged in value from as little as $2.2 up to $5.44. A popular way to gauge a stock's volatility is its "beta".

IMMP.US volatility(beta: 1.54)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Immutep's is 1.536. This would suggest that Immutep's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

How has Coronavirus impacted Immutep's stock price?

Since the stock market crash in March caused by coronavirus, Immutep's stock price has had significant positive movement.

Its last market close was $3.14, which is 10.51% up on its pre-crash value of $2.81 and 492.45% up on the lowest point reached during the March crash when the stocks fell as low as $0.53.

If you had bought $1,000 worth of Immutep stocks at the start of February 2020, those stocks would have been worth $800.01 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,427.29.

Immutep overview

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc. , Merck & Co.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site